DEMAPHARMA
ActiveSummary
DEMAPHARMA has been active since 2006 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €385,336 and a net result of €17,290. Equity is growing by about 11% per year across the filed financial years. Its solvency ranks better than 72% of 12,661 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
09-07
NBB filing
Annual accounts filed
financial year 2025 · abbreviated format
2025
23-08
NBB filing
Annual accounts filed
financial year 2024 · full format · 23 days late
2024
30-08
NBB filing
Annual accounts filed
financial year 2023 · micro format · 30 days late
2023
31-12
Financial
Highest result from 2018 to 2025net €47,132 ▲61.4%
Operating result €80,698, net result €47,132, both a record.
23-05
NBB filing
Annual accounts filed
financial year 2022 · micro format
2022
31-08
NBB filing
Annual accounts filed
financial year 2021 · micro format · 31 days late
2021
26-07
NBB filing
Annual accounts filed
financial year 2020 · micro format
2020
30-11
NBB filing
Annual accounts filed
financial year 2019 · micro format · 122 days late
2019
31-12
Financial
Equity above €200,000equity €207,826 ▲21.5%
A profit in every financial year since 2018 builds equity to €207,826.
30-08
NBB filing
Annual accounts filed
financial year 2018 · full format · 30 days late
2018
27-09
NBB filing
Annual accounts filed
financial year 2017 · full format · 58 days late
2017
29-08
NBB filing
Annual accounts filed
financial year 2016 · full format · 29 days late
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.Of the 19 annual accounts filed, the latest 10 are here; all 19 are under Financials.
0 of 2 deeds read
About the unread acts
We know of 2 Belgian Official Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.